Lanean...
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
BACKGROUND: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with poor prognosis of patients with ovarian cancer. AIM: In this study, w...
Gorde:
| Argitaratua izan da: | J Ovarian Res |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465006/ https://ncbi.nlm.nih.gov/pubmed/26055813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-015-0166-y |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|